Phase II Trial of CC-5013 (Lenalidomide, Revlimid) in Patients With Cutaneous T-Cell Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Lenalidomide (Primary)
- Indications Mycosis fungoides; Sezary syndrome
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 31 Aug 2018 Biomarkers information updated
- 24 Jan 2018 Planned End Date changed from 1 Feb 2018 to 1 Feb 2020.
- 24 Jan 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.